A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer: A study of the Eastern Cooperative Oncology Group (E2185)

Cancer

Volumn 77, Issue 3, 1996, Pages 483-489

  Cobau, Charles D ^a   Declercq, Katrien ^b   Neuberg, Donna ^b   Ingle, James N ^c   Tormey, Douglass C ^d  

^a Flower Hospital   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

breast cancer; hormone responsive; megace; metastatic; premarin; randomized trial; treatment

Indexed keywords

ANTIESTROGEN; CONJUGATED ESTROGEN; ESTROGEN RECEPTOR; MEGESTROL ACETATE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MEDICAL RECORD; METASTASIS; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT FAILURE; VAGINA BLEEDING;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEGESTROL; MEGESTROL ACETATE; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; SURVIVAL RATE;

EID: 0030048427     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960201)77:3<483::AID-CNCR9>3.0.CO;2-L     Document Type: Article

References (18)

1. Escher GC, Heber JM, Woodward HZ, Farrow JH, Adair FE. New steroids in the treatment of advanced mammary carcinoma. In: Symposium on steroids in experimental and clinical Practice. White A, editor. New York: The Blakiston Company, 1951:402.
2. Hsueh AJW, Peck EL, Clark JH. Progesterone antagonism of the estrogen receptor and estrogen-induced uterine growth. Nature 1975;253:337-9.
3. David A, Edwards K, Fellows KP, Plummer JM. Anti-ovulatory and other biological properties of megestrol acetate. J Reprod Fertil 1963;5:331-46.
4. Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM, et al. A controlled trial of megestrol acetate in patients with cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127-32.
5. Ansfield FJ, David HL Jr, Ramirez G, Davis TM, Borden EC, Johnson RO, et al. Further clinical studies with megestrol acetate in advanced breast cancer. Cancer 1976;38:53-5.
6. Alexieva-Figusch J, van Gilse HA, Hop WCJ, Phoa CH, Blonkvd Wijst J, Treurniet RE. Progestin therapy in advanced breast cancer: megestrol acetate - an evaluation of 160 treated cases. Cancer 1980;46:2369-72.
7. Ross MB, Buzdar AU, Blumenschein GR. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer 1982;49:413-7.
8. Morgan LR, Donley PJ. Tamoxifen versus megestrol acetate in breast cancer. Symposium on anti-hormones and breast cancer. Macclesfield, UK: Pharmaceutical Division of ICI, 1981:301-4.
9. Bonomi P, Johnson P, Anderson K, Wolter J, Bunting N, Strauss A, et al. Primary hormonal control of advanced breast cancer with megestrol acetate: predictive value of estrogen receptor and progestrone receptor levels. Semin Oncol 1985;(Suppl 1):48-54.
10. Horowitz KB, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: correlation with nuclear processing of estrogen receptor. J Biochem (Tokyo) 1978;253:2223-8.
11. Horowitz KB, Koseki Y, Mcguire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 1978;103:1742-51.
12. Jordan VC, Dix CJ, Naylor KE, Prestwich G, Roswsby L. Nonsteroidal antiestrogens: their biologic effects and potential mechanisms of action. J Toxicol Environ Health 1978;4:363.
13. Namer M, Lalanne C, Baulier E. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. Cancer Res 1980;40:1750-2.
14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA 1958;53:457-81.
16. Peto R, Peto J. Asymptotically efficient rank invariant test procedures (with discussion). J Roy Statist Soc Ser A 1972;135:185-206.
17. Cox DR. Regression models and life tables (with discussion). J Roy Statist Soc Ser B 1972;34:187-220.
18. Rosner B. Fundamentals of biostatistics. 3rd edition. Boston: PWS-Kent, 1990:336-42.